Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction (Review)
Authors: Kiyoshi Kikuchi
Ko Ichi Kawahara
Hisaaki Uchikado
Naohisa Miyagi
Terukazu Kuramoto
Tomoya Miyagi
Yoko Morimoto
Takashi Ito
Salunya Tancharoen
Naoki Miura
Kazunori Takenouchi
Yoko Oyama
Binita Shrestha
Fumiyo Matsuda
Yoshihiro Yoshida
Shinihiro Arimura
Kentaro Mera
Ko Ichi Tada
Narimasa Yoshinaga
Ryuichi Maenosono
Yoshiko Ohno
Teruto Hashiguchi
Ikuro Maruyama
Minoru Shigemori
Yame General Hospital
Division of Laboratory and Vascular Medicine
Department of Maxillofacial Diagnostic and Surgical Science
Kagoshima University Faculty of Medicine
Kagoshima University
Kurume University School of Medicine
Omuta City General Hospital
Mahidol University
Keywords: Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology
Issue Date: 1-Sep-2011
Citation: Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 771-775
Abstract: Edaravone was originally developed as a potent free radical scavenger and has been widely used to treat cerebral infarction in Japan since 2001. Several free radical scavengers have been developed and some of them have progressed to clinical trials for the treatment of cerebral infarction. One such scavenger, edaravone, has been approved by the regulatory authority in Japan for the treatment of patients with cerebral infarction. Of particular interest is the ability of edaravone to diffuse into the central nervous system in various neurologic diseases. Aside from its hydroxyl radical scavenging effect, edaravone has been found to have beneficial effects on inflammation, matrix metalloproteinases, nitric oxide production and apoptotic cell death. Concordantly, edaravone has been found to have neuroprotective effects in a number of animal models of disease, including stroke, spinal cord injury, traumatic brain injury, neurodegenerative diseases and brain tumors. The proven safety of edaravone following 9 years of use as a free radical scavenger suggests that it may have potential for development into an effective treatment of multiple neurologic conditions in humans.
ISSN: 17921015
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.